Bicycle Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BCYC and other ETFs, options, and stocks.

About BCYC

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. 

CEO
Kevin Lee
CEOKevin Lee
Employees
288
Employees288
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
2009
Founded2009
Employees
288
Employees288

BCYC Key Statistics

Market cap
275.69M
Market cap275.69M
Price-Earnings ratio
-1.25
Price-Earnings ratio-1.25
Dividend yield
Dividend yield
Average volume
828.95K
Average volume828.95K
High today
$4.10
High today$4.10
Low today
$3.96
Low today$3.96
Open price
$4.00
Open price$4.00
Volume
400.82K
Volume400.82K
52 Week high
$9.18
52 Week high$9.18
52 Week low
$3.95
52 Week low$3.95

BCYC News

TipRanks 7d
Bicycle Therapeutics Shareholders Approve Proposals at 2026 AGM

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.